Activity of Serum Enzymes in Puromycin Aminonucleoside-Induced Nephrotic Syndrome

References

• Bernard DB. Metabolic abnormalities in nephrotic syndrome: pathophysiology and complications. The Nephrotic Syndrome. Contemporary Issues in Nephrology, BM Brenner, JH Stein. Churchill Livingstone, New York 1982; Vol 9: 85–119
   Google Scholar
• Pedraza-Chaverri J, Cruz C, Ibarra-Rubio M E, et al. Pathophysiology of experimental nephrotic syndrome induced by puromy-cin aminonucleoside in rats. I. The role of proteinuria, hypoproteinemia and renin-angiotensin-aldosterone system on sodium retention. Rev Invest Clin 1990; 42: 29–38
   PubMedGoogle Scholar
• Pedraza-Chaverri J, Cruz C, ChÁVez M T, et al. Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. II. In vitro release of renin, angiotensinogen and aldosterone. Rev Invest Clin 1990; 42: 120–126
   PubMedGoogle Scholar
• Pedraza-Chaverri J, Cruz C, ChÁVez M, Ibarra- T., Rubio M E, Tapia E, PeNˆA JC. Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. III. Effect of captopril, an angiotensin converting enzyme inhibitor, on proteinuria and sodium retention. Rev Invest Clin 1990; 42: 210–216
   PubMedGoogle Scholar
• Lewandowski A E, Liao W SL, Stinson-Fisher C A, Kent J D, Jefferson LS. Effects of experimentally induced nephrosis on protein synthesis in rat liver. Am J Physiol 1988; 254: C634–C642
   Google Scholar
• Beaman M, Oldfield S, Maclennan I CM, Michael J, Adu D. Hypogammaglobulinaemia in nephrotic rats is attributable to hyper-catabolism of IgG. Clin Exp Immunol 1988; 74: 425–430
   PubMedGoogle Scholar
• Housley J, Jones L, Harvey A. Serum a-macroglobulins in rat aminonucleoside nephrosis. Clin Chim Acta 1968; 21: 85–90
   PubMedGoogle Scholar
• Ibarra-Rubio M E, Cruz C, Tapia E, Pena J C, Pedraza-Chaverri J. Serum angiotensin converting enzyme activity and plasma renin activity in experimental models of rats. Clin Exp Pharmacol Physiol 1990; 17: 391–399
   PubMed Web of Science ®Google Scholar
• ArÉValo A E, Ibarra-Rubio M E, Cruz C, Pena J C, Pedraza-Chaverri J. Angiotensin-I-converting enzyme activity in puromycin aminonucleoside-nephrotic syndrome. Clin Chim Acta 1990; 191: 175–184
   PubMed Web of Science ®Google Scholar
• Girot R, Jaubert F, Leon M., et al. Albumin, fibrinogen, prothrombin and antithrombin III variations in blood, urines and liver in rat nephrotic syndrome (Heymann nephritis). Tromb Haemostas 1983; 49: 13–17
   PubMedGoogle Scholar
• Marsh NA. The fibrinolytic enzyme system of the rat: the effect of aminonucleoside-induced nephrotic syndrome. Br J Exp Pathol 1969; 50: 1–12
   PubMedGoogle Scholar
• Ley E, Ziv E, Bar-On H, Sahfrir E. Chylomicron synthesis in experimental nephrotic syndrome. Biochim Biophys Acta 1989; 1005: 20–26
   PubMedGoogle Scholar
• Gherardi E, Calandra S. Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside. Biochim Biophys Acta 1981; 710: 188–196
   Google Scholar
• Davies R W, Staprans I, Hutchinson F N, Kaysen GA. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990; 86: 600–605
   PubMedGoogle Scholar
• Alfrey A C, Hammond WS. Renal iron handling in the nephrotic syndrome. Kidney Int 1990; 37: 1409–1413
   PubMedGoogle Scholar
• Chan Y-L, Mason R S, Parmentier M, Savdie E, Lissner D, Posemn S. Vitamin D metabolism in nephrotic rats. Kidney Int 1983; 24: 336–341
   PubMedGoogle Scholar
• Khamise G, Vaziri N D, Oveisi F, Ahmadnia M R, Ahmadnia L. Vitamin D absorption, plasma concentration and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome. Proc Soc Exp Biol Med 1991; 196: 210–213
   PubMedGoogle Scholar
• Pedraza-Chaverri J, Cruz C, Ibarra-Rubio M E, HernÁNdez C, Tapia E, PeNˆA JC. Urinary excretion of renin and angiotensino-gen in nephrotic rats. Nephron 1991; 57: 106–108
   PubMedGoogle Scholar
• Pedraza-Chaverri J, Cruz C, Sandoval A A, Tapia E, Pena JC. Effect of captopril on urinary excretion of renin and angiotensino-gen in aminonucleoside nephrosis. Renal Failure 1992; 14: 155–159
   PubMed Web of Science ®Google Scholar
• Shafrir E, Levy E, Deckelbaum R. Urinary excretion of apoli-poproteins bound to HDL-like particles in rat nephrotic syndrome and their relation to plasma HDL. Nephron 1990; 56: 24–29
   PubMedGoogle Scholar
• Sibley J A, Lehninger AL. Determination of aldolase in animal tissues. J Biol Chem 1949; 177: 859–872
   PubMed Web of Science ®Google Scholar
• Rappaport F, Fischi J, Pinto N. An improved method for the estimation of cholinesterase activity in serum. Clin Chim Acta 1959; 4: 227–230
   PubMed Web of Science ®Google Scholar
• Martinek R G, Berger L, Broida D. Simplified estimation of leucine aminopeptidase (LAP) activity. Clin Chem 1964; 10: 1087–1092
   PubMedGoogle Scholar
• King J. Isocitrate dehydrogenase. Colorimetric assay. Methods of Enzymatic Analysis2nd ed., HU Bergmeyer. Academic Press, New York 1974; Vol 2: 627–629
   Google Scholar
• Karmen S. A note on the spectrophotometric assay of glutamic oxalacetic transaminase in human blood serum. J Clin Invest 1955; 34: 131–135
   PubMed Web of Science ®Google Scholar
• WrÓBleski F, Ladue JS. Serum glutamic-pyruvic transaminase in cardiac and hepatic disease. Proc Soc Exp Biol Med 1956; 91: 569–571
   PubMedGoogle Scholar
• Howel B F, McClure S, Schaffer R. Lactate-to-pyruvate or pyruvate-to-lactate assay for lactate dehydrogenase: reexamination. Clin Chem 1979; 25: 269–272
   PubMedGoogle Scholar
• Rosalki S B, Wilkinson JH. Reduction of α-ketobutyrate by human serum. Nature 1960; 188: 1110–1111
   PubMed Web of Science ®Google Scholar
• Elliot B A, Wilkinson JH. a-Hydroxybutyric dehydrogenase in myocardial infarction and in liver disease. Lancet 1961; 1: 698–699
   PubMed Web of Science ®Google Scholar
• Oliver IT. A spectrophotometric method for the determination of creatine phosphokina.se and myokinase. Biochem J 1955; 61: 696–705
   PubMedGoogle Scholar
• Rosalki SB. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med 1967; 69: 696–705
   PubMed Web of Science ®Google Scholar
• Bessey O, Lowry O H, Brock MJ. Method for the determination of alkaline phosphatase with five cubic millimeters of serum. J Biol Chem 1946; 164: 321–329
   PubMed Web of Science ®Google Scholar
• Naftalin L, Sexton M, Whitaker J F, Tracey D. A routine procedure for estimating serum gamma-glutamyl transpeptidase activity. Clin Chim Acta 1969; 26: 293–296
   PubMed Web of Science ®Google Scholar
• Doumas B T, Biggs HG. Determination of serum albumin. Standard methods of clinical chemistry, GR Cooper. Academic Press, New York 1972; Vol 7: 175–188
   Google Scholar
• Lowry O A, Rosenbrought NJ., Farr A L, Randall RJ. Protein measurements with the Folin phenol reagent. J Biol Chem 1951; 193: 265–272
   PubMed Web of Science ®Google Scholar
• Baker B R, Joseph J P, Williams JH. Puromycin. Synthetic studies. VII. Partial synthesis of amino acid analogs. J Am Chem Soc 1954; 76: 2838
   Google Scholar
• Nathans D, Neidle A. Structural requirements for puromycin inhibition of protein synthesis. Nature 1963; 197: 1076–1077
   PubMed Web of Science ®Google Scholar
• Rabinovitz M, Fisher JM. A dissociative effect of puromycin on the pathway of protein synthesis by Ehrlich ascitis tumor cells. J Biol Chem 1962; 237: 477–481
   PubMedGoogle Scholar
• Frenk S, Antonowics J M, Craig J M, Metcoff J. Experimental nephrotic syndrome induced in rats by aminonucleoside. Renal lesions and body electrolyte composition. Proc Soc Exp Biol Med 1955; 89: 424–421
   PubMed Web of Science ®Google Scholar
• Fiegelson E B, Drake J W, Recant L. Experimental amino-nucleoside nephrosis in rats. J Lab Clin Med 1957; 50: 437–446
   PubMedGoogle Scholar
• Hartman ME. Some metabolic and structural characteristics of experimental nephrosis. Am Heart J 1959; 58: 483–485
   PubMedGoogle Scholar
• Feldman J D, Fisher ER. Renal lesions of aminonucleoside nephrosis as revealed by electron microscopy. Lab Invest 1959; 8: 371–385
   PubMedGoogle Scholar
• Vernier R L, Papermaster B W, Good RA. Aminonucleoside nephrosis. I. Electron microscopic study of the renal lesions in rats. J Exp Med 1959; 109: 115–126
   PubMed Web of Science ®Google Scholar
• Jensen H. Plasma protein and lipid pattern in the nephrotic syndrome. Acta Med Scand 1967; 182: 465–473
   PubMedGoogle Scholar
• Steines W J, Mehl JW. The elevation of a2-macroglobulin and trypsin-binding activity in nephrosis. J Lab Clin Med 1966; 67: 559–565
   Google Scholar
• Vaziri N D, Gonzales E, Barton C H, Chen H T, Nguyen Q, Arquilla M. Factor XIII and its substrates, fibrinogen, and α2-antiplasmin, in plasma and urine of patients with nephrosis. J Lab Clin Med 1991; 117: 152–156
   PubMedGoogle Scholar
• Vaziri N D, Branson H E, Ness R. Changes of coagulation factors IX, VIII, VII, X, and V in nephrotic syndrome. Am J Med Sci 1980; 280: 167–171
   PubMedGoogle Scholar
• Scott T, Egelson M. Concise Encyclopedia of Biochemistry. Walter de Gruyter, Berlin 1988
   Google Scholar
• Fasman GD. CRC Practical Handbook of Biochemistry & Molecular Biology. CRC Press, Boca Raton, FL 1990
   Google Scholar
• Murray RL. Alanine aminotransferase. Methods in Clinical Chemistry, AJ Pesce, LA Kaplan. Mosby, St. Louis 1987; 1062–1065
   Google Scholar
• Tsuji A, Matsuda Y, Katunuma N. Characterization of human serum gamma-glutamyltranspeptidase. Clin Chim Acta 1980; 104: 361–366
   PubMedGoogle Scholar
• Pedraza-Chaverri J, Huberman A. Actinomycin D blocks the hepatic functional albumin-mRNA increase in aminonucloeoside-nephrotic rats. Nephron 1991; 59: 648–650
   PubMedGoogle Scholar
• Zimerman H J, Henry JB. Clinical enzymology. Clinical diagnosis and management by laboratory methods17th ed., JB Henry. Saunders, Philadelphia 1979; Vol 1: 347–384
   Google Scholar
• Vorhaus L J, Kark RM. Serum cholinesterase in health and disease. Am J Med 1953; 14: 707–719
   PubMed Web of Science ®Google Scholar
• Alexander C S, Nagasawa H T, Filbin D. Distribution and excretion of aminonucleoside-8-C14 in normal and nephrotic rats. Proc Soc Exp Biol Med 1962; 111: 521–526
   PubMedGoogle Scholar
• Derr R F, Alexander C S, Nagasawa HT. Metabolism of puromycin aminonucleoside in (he normal, “prenephrolic,” and nephrotic rat. Proc Soc Exp Biol Med 1967; 125: 248–252
   PubMed Web of Science ®Google Scholar
• Nagasawa H T, Swingle K F, Alexander CS. Metabolism of aminonucleoside-8-l4C in the rat and guinea pig. Biochem Pharmacol 1967; 16: 2211–2219
   PubMedGoogle Scholar
• Van Der Vijgh W JF, Van Vezen D, Van Der Poort J SEM. Morphometry study of myocardial changes during puromycin aminonucleoside induced nephropathy in rats. Anticancer Res 1987; 7: 1111–1116
   PubMedGoogle Scholar
• Lewin P K, Moscarello MA. Liver ultrastructural and biochemical changes in the prenephrotic stage of aminonucleoside nephrosis. Exp Mol Pathol 1968; 8: 21–33
   PubMedGoogle Scholar
• Katona E, Moscarello MA. Early effects of aminonucleoside on enzymes in the Golgi apparatus of rat liver. Can J Physiol Pharmacol 1975; 53: 549–554
   PubMedGoogle Scholar
• Katona E. Very early effects of aminonucleoside on some rat liver enzymes. Biochem Pharmacol 1974; 23: 2199–2202
   PubMedGoogle Scholar
• Farqhuar M G, Palade GE. Glomerular permeability. II. Ferritin transfer across the glomerular capillary wall in nephrotic rats. J Exp Med 1961; 114: 699–741
   PubMedGoogle Scholar
• Venkatachalam M A, Cotran R S, Karnovsky MJ. An ultrastructural study on glomerular permeability in aminonucleoside nephrosis using catalase as tracer protein. J Exp Med 1970; 142: 1168–1180
   Google Scholar
• Price R G, Ellis BG. Urinary enzyme excretion in amino-nucleoside nephrosis in rats. Chem-Biol Interac 1976; 13: 353–358
   PubMedGoogle Scholar